

BIBLIOGRAPHIC RESOURCES

1. Topham MK. Signaling Roles of Diacylglycerol Kinases. (2006) *Journal of Cellular Biochemistry* 97:474-484.
2. Topham MK and Prescott SM. Mammalian Diacylglycerol Kinases, a Family of Lipid Kinases with Signaling Functions. (1999) *The Journal of Biological Chemistry* 274:11447-11450.
3. Imai S, Kai M, Yasuda S, Kanoh H, and Sakane F. Identification and Characterization of a Novel Human Type II Diacylglycerol Kinase, Dgk- κ . *The Journal of Biological Chemistry* 280:39870-39881.
4. Avila-Flores A, Santos T, Rincon E, and Merida I. Modulation of the mTOR Pathway by Diacylglycerol Kinase-Produced Phosphatidic Acid. (2005) *The Journal of Biological Chemistry* 280:10091-10099.
5. Ligeti E, Dagher MC, Hernandez SE, Koleske AJ, and Settleman J. Phospholipids Can Switch the GTPase Substrate Preference of a GTPase-activating Protein. (2004) *The Journal of Biological Chemistry* 279: 5055-5058.
6. Chuang TH, Bohl BP, and Bokoch GM. Biologically Active Lipids Are Regulators of Rac-GDI Complexation (1993). *The Journal of Biological Chemistry* 268:26206-26211.
7. Ugolev Y, Molshanski-Mor S, Weinbaum C, and Pick E. Liposomes Comprising Anionic but not Neutral Phospholipids Cause Dissociation of [Rac(1 or 2)-RhoGDI] Complexes and Support Amphiphile-Independent NADPH Oxidase Activation by Such Complexes. (2006) *The Journal of Biological Chemistry* 281:19204-19219.
8. Hurley JH, Newton AC, Parker PJ, Blumberg PM, and Nishizuka Y. Taxonomy and function of C1 protein kinase C homology domains. (1997) *Protein Sci.* 6:447-480.
9. Cipres A, Carrasco S, Merino E, Diaz E, Krishna UM, Falck JR, Martinez-A C, and Merida I. Regulation of Diacylglycerol Kinase α by Phosphoinositide 3-Kinase Lipid Products. (2003) *The Journal of Biological Chemistry* 278: 35629-35635.
10. Jones DR, Pettitt TR, Sanjuan MA, Merida I, Wakelam JO. Interleukin-2 Causes an Increase in Saturated/Monosaturated Phosphatidic Acid Derived from 1,2-Diacylglycerol and 1-O-Alkyl-2-acylglycerol. (1999) *The Journal of Biological Chemistry* 274:16846-16853.
11. Flores I, Jones DR, Cipres A, Flores-Diaz E, Sanjuan MA, and Merida I. Diacylglycerol Kinase Inhibition Prevents IL-2-Induced G_i to S Transition Through a Phosphatidylinositol-3 Kinase-Independent Mechanism. (1999) *The Journal of Immunology* 163:708-714.
12. Carrasco S and Merida I. Diacylglycerol-dependent Binding Recruits PKC θ and RasGRP1 C1 domains to Specific Subcellular Localizations in Living T Lymphocytes. (2004) *Molecular Biology of the Cell* 15:2932-2942.
13. Sanjuan MA, Jones DR, Izquierdo M, and Merida I. Role of Diacylglycerol Kinase α in the Attenuation of Receptor Signaling. (2001) *The Journal of Cell Biology* 153:207-219.
14. Diaz-Flores E, Siliceo M, Martinez-A C, and Merida I. Membranes Translocation of Protein Kinase C θ during T Lymphocyte Activation Requires Phospholipase C- γ -generated Diacylglycerol. (2003) *The Journal of Biological Chemistry* 278:28208-29215.
15. Sanjuan MA, Pradet-Balade B, Jones DR, Martinez-A C, Stone JC, Garcia-Sanz JA, and Merida I. T Cell Activation In Vivo Targets Diacylglycerol Kinase α to the Membrane: A Novel Mechanism for Ras Attenuation. (2003) *The Journal of Immunology* 170:2877-2883.
16. Olenchock BA, Guo R, Carpenter JH, Jordan M, Topham MK, Koretzky GA, and Zhong X-P. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. (2006) *Nature Immunology* 7:1174-1181.
17. Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, Praveen K, Stang S, Stone JC, and Gajewski TF. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase- α . (2006) *7:1166-1173*.
18. Bacchiocchi R., Baldanzi G, Carbonari D, Capomagi C, Colombo E, van Blitterswijk WJ, Graziani A, and Fazioli F. Activation of α -Diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase. (2005) *Blood* 106:2175-2182.
19. Cutrupi S, Baldanzi G, Gramaglia D, Maffè A, Schaap D, Giraudo E, van Blitterswijk W, Bussolino F, Comoglio PM, and Graziani A. Src-mediated activation of alpha-diacylglycerol kinase is required for hepatocyte growth factor-induced cell motility. (2000) *EMBO J.* 19:4614-4622.
20. Baldanzi G, Mitola S, Cutrupi S, Filigheddu N, van Blitterswijk WJ, Sinigaglia F, Bussolino F, and Graziani A. Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro. (2004) *Oncogene* 23:4828-4838.

21. Mareel M and Leroy A. Clinical, Cellular, and Molecular Aspects of Cancer Invasion. (2002) *Physiology Review* 83:337-376.
22. Boccaccio C and Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. (2006) *Nature Rev Cancer* 6:637-645.
23. Corso S, Comoglio PM, and Giordano S. Cancer therapy: can the challenge be MET? (2005) *TRENDS in Molecular Medicine* 11:284-292.
24. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, and Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. (2002) *Cytokine & Growth Factor Reviews* 13:41-59.
25. Zhang Y-W and Vande Woude GF. HGF/SF-Met Signaling in the Control of Branching Morphogenesis and Invasion. (2003) *Journal of Cellular Biochemistry* 88:408-417.
26. Small JV, Stradal T, Vignal E, and Rottner K. The lamellipodium; where motility begins. (2002) *TRENDS in Cell Biology* 12:112-120.
27. Yamazaki D, Kurisu S, and Takenawa T. Regulation of cancer cell motility through actin reorganization. (2005) *Cancer Sci.* 96:379-386.
28. Moissoglu K, Slepchenko BM, Meller N, Horwitz AF, and Schwartz MA. In vivo dynamics of Rac-membrane interactions. (2006) *Molecular Biology of the Cell* 17:2770-2779.
29. Del Pozo MA, Alderson NB, Kiosses WB, Chiang HH, Anderson RG, and Schwartz MA. Integrins regulate Rac targeting by internalization of membrane domains. (2004) *Science* 303:839-842.
30. Del Pozo MA, Kiosses WB, Alderson NB, Meller N, Hahn KM, and Schwartz MA. Integrins regulate GTP-Rac localized effector interactions through dissociation of Rho-GDI. (2002) *Nature Cell Biology* 4:232-239.
31. Del Pozo MA, Price LS, Alderson NB, Ren XD, and Schwartz MA. Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. (2000) *The EMBO Journal* 19:2008-2014.
32. Takenawa T and Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. (2007) *Nature Reviews Molecular Cell Biology* 8:37-48.
33. Martin KH, Slack JK, Boerner SA, Martin CC, and Parsons JT. Integrin Connection Map: To Infinity and Beyond. (2002) *Science* 296:1652-1653.
34. Brown MC and Turner CE. Paxillin: Adapting to Change. (2004) *Physiol. Rev.* 84:1315-1339.
35. Roskoski RJ. Src protein-tyrosine kinase structure and regulation. (2004) *Biochemical and Biophysical Research Communications* 324:1155-1164.
36. Bromann PA, Korkaya H, and Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. (2004) *Oncogene* 23:7957-7968.
37. Playford MP and Schaller MD. The interplay between Src and integrins in normal and tumor biology. (2004) *Oncogene* 23:7928-7946.
38. Sugimoto Y, Whitman M, Cantley LC, and Erikson RL. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. (1984) *Proc. Natl. Acad. Sci. USA* 81:2117-2121.
39. Fukunaga-Takenaka R, Shirai Y, Yagi K, Adachi N, Sakai N, Merino E, Merida I, and Saito N. Importance of chroman ring and tyrosine phosphorylation in the subtype-specific translocation and activation of diacylglycerol kinase α by D- α -tocopherol. (2005) *Genes to Cells* 10:311-319.
40. Sandilands E, Cans C, Fincham VJ, Brunton VG, Mellor H, Prendergast CG, Norman JC, Superti-Furga G and Frame MC. RhoB and actin polymerization coordinate Src activation via endosome-mediated delivery to the membrane. (2004) *Dev. Cell* 7:855-869.
41. Caloca MJ, Wang H, and Kazanietz MG. Characterization of the Rac-GAP (Rac-GTPase activating protein) activity of beta2-chimaerin, a 'non-protein kinase C' phorbol ester receptor. (2003) *Biochem J.* 375:313-321.
42. Canagarajah B, Leskow FC, Ho JY, Mischak H, Saidi LF, Kazanietz MG, and Hurley JH. Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin. (2004) *Cell* 119:407-418.
43. Wang H, Yang C, Leskow FC, Sun J, Canagarajah B, Hurley JH, and Kazanietz MG. Phospholipase C gamma/diacylglycerol-dependent activation of beta2-chimaerin restricts EGF-induced Rac signaling. (2006) *EMBO J.* 25:2062-2074.

44. Tsushima S, Kai M, Yamada K, Imai S, Houkin K, Kanoh H, and Sakane F. Diacylglycerol kinase gamma serves as an upstream suppressor of Rac1 and lamellipodium formation. (2004) *J. Biol. Chem.* 279:28603-28613.
45. Yasuda S, Kai M, Imai S, Kanoh H, and Sakane F. Diacylglycerol kinase γ interacts with and activates b2-chimaerin, a Rac-specific GAP, in response to epidermal growth factor. (2007) *FEBS Lett.* 581:551-557.
46. Jenkins GH, Fiset PL, and Anderson R. Type I Phosphatidylinositol 4-Phosphate 5-Kinase Isoforms Are Specifically Stimulated by Phosphatidic Acid. (1994) *J. Biol. Chem.* 269:11547-11554.
47. Luo B, Prescott SM, and Topham MK. Diacylglycerol Kinase ζ regulates phosphatidylinositol 4-phosphate 5-kinase $I\alpha$ by a novel mechanism. (2004) *Cell Signall.*16:891-897.
48. Tolia KF, Couvillon AD, Canley LC, and Carpenter CL. Characterization of a Rac1- and RhoGDI-associated lipid kinase signaling complex. (1998) *Mol. Cell. Biol.* 18:762-770.
49. Chuang T-H, Bohl BP, and Bokoch GM. Biologically active lipids are regulator of Rac-GDI complexation. (1993) *J. Biol. Chem.* 268:26206-26211.
50. Ugolev Y, Molshanski-Mor S, Weinbaum C, and Pick E. Liposomes comprising anionic but not neutral phospholipids cause dissociation of [Rac(1 or 2)-RhoGDI] complexes and support amphiphile-independent NADPH oxidase activation by such complexes. (2006) *J. Biol. Chem.* 281:19204-19219.
51. Ligeti E, Dagher MC, Hernandez SE, Koleske AJ, and Settleman J. Phospholipids Can Switch the GTPase Substrate Preference of a GTPase-activating Protein. (2004) *J. Biol. Chem.* 279:5055-5058.
52. Howard HD, Feighner SD, Cully DF, Arena JP, Liberators PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong S-S, Chaung L-Y, Elbrecht A, Dashkevich M, Heavens R, Rigby M, Sirinathsinghji DJS, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffith PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LHT. A receptor in pituitary and hypothalamus that functions in growth hormone release. (1996) *Science* 273: 974-976.
53. McKee KK, Palyha OC, Feighner SD, Hreniuk DL, Tan CP, Phillips MS, Smith RG, Van der Ploeg LH, Howard AD. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. (1997) *Mol. Endocrinol.* 11: 415-423.
54. Smith RG, Feighner S, Prendergast K, Guan X, and Howard A. A new orphan receptor involved in pulsatile growth hormone release. (1999) *Trends Endocrinol Metab* 10: 128-135.
55. Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM, Zeng Z, Williams DL Jr, Feighner SD, Nunes CN, Murphy B, Stair JN, Yu H, Jiang Q, Clements MK, Tan CP, McKee KK, Hreniuk DL, McDonald TP, Lynch KR, Evans JF, Austin CP, Caskey CT, Van der Ploeg LH, and Liu Q. Identification of receptors for neuromedin U and its role in feeding. (2000) *Nature* 406: 70-74.
56. Vincent JP, Mazella J, and Kitabgi P. Neurotensin and neurotensin receptors. (1999) *Trends Pharmacol Sci* 20: 302-309.
57. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. (1999) *Nature* 402: 656-660.
58. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K. Ghrelin stimulates gastric acid secretion and motility in rats. (2000) *Biochem Biophys Res Commun* 276: 905-908.
59. Hosoda H, Kojima M, Mizushima T, Shimizu S and Kangawa K. Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by posttranslational processing. (2003) *J Biol Chem* 278: 64-70.
60. Hosoda H, Kojima M, Matsuo H, and Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. (2000) *Biochem Biophys Res Commun* 279: 909-913.
61. Beaumont NJ, Skinner VO, Tan TM, Ramesh BS, Byrne DJ, MacColl GS, Keen JN, Bouloux PM, Mikhailidis DP, Bruckdorfer KR, Vanderpump MP, and Srai KS. Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. (2003) *J Biol Chem* 278: 8877-8880.
62. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. (2001) *J Clin Endocrinol Metab* 86: 4753-4758.
63. Gualillo O, Caminos J, Blanco M, Garcia-Caballero T, Kojima M, Kangawa K, Dieguez C, Casanueva FF. Ghrelin, a novel placental-derived hormone. (2001) *Endocrinology* 142: 788-794.
64. Tena-Sempere M, Barreiro ML, Gonzalez LC, Gaytan F, Zhang FP, Caminos JE, Pinilla L, Casanueva FF, Dieguez C and Aguilar E. Novel expression and functional role of ghrelin in rat testis. (2002) *Endocrinology* 143: 717-725.

65. Mori K, Yoshimoto A, Takaya K, Hosoda K, Ariyasu H, Yahata K, Mukoyama M, Sugawara A, Hosoda H, Kojima M, Kangawa K, Nakao K. Kidney produces a novel acylated peptide, ghrelin. (2000) *FEBS Lett* 486: 213–216.
66. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K, Grossman AB. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. (2001) *J Clin Endocrinol Metab* 86: 881–887.
67. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. (2000) *Endocrinology* 141: 4255–4261.
68. Volante M, Allia E, Gugliotta P, Funaro A, Broglio F, Deghenghi R, Muccioli G, Ghigo E, Papotti M. Expression of ghrelin and of GHS receptor by pancreatic islet cells and related endocrine tumors. (2002) *J Clin Endocrinol Metab* 87: 1300–1308.
69. Hattori N, Saito T, Yagyu T, Jiang BH, Kitagawa K, Inagaki C. GH, GH receptor, GH Secretagogue receptor and ghrelin expression in human t cells, b cells and neutrophils. (2001) *J Clin Endocrinol Metab* 86: 4284–4291.
70. Lu S, Guan JL, Wang QP, Uehara K, Yamada S, Goto N, Date Y, Nakazato M, Kojima M, Kangawa K and Shioda S. Immunocytoical observation of ghrelin-containing neurons in the rat arcuate nucleus. (2002) *Neurosci Lett* 321: 157–160.
71. Volante M, Fulcheri E, Allia E, Cerrato M, Pucci A, and Papotti M. Ghrelin expression in fetal, infant, and adult human lung. (2002) *J Histochem Cytochem* 50:1013–1021.
72. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. (2002) *J Clin Endocrinol Metab* 87: 2988–2991.
73. Gaytan F, Barreiro ML, Chopin LK, Herington AC, Morales C, Pinilla L, Casanueva FF, Aguilar E, Dieguez C, Tena-Sempere M. Immunolocalization of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor, in the cyclic human ovary. (2003) *J Clin Endocrinol Metab* 88: 879–887.
74. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. (2001) *Diabetes* 50: 1714–1719.
75. Tschöp M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R, Folwaczny C. Post-prandial decrease of circulating human ghrelin levels. (2001) *J Endocrinol Invest* 24: RC19–RC21.
76. Kohno D, Gao HZ, Muroya S, Kikuyama S and Yada T. Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca(2+) signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. (2003) *Diabetes* 52: 948–956.
77. Arosio M, Ronchi CL, Gebbia C, Cappiello V, Beck-Peccoz P, Peracchi M. Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels. (2003) *J Clin Endocrinol Metab* 88: 701–704.
78. Zhang W, Chen M, Chen X, Segura BJ, Mulholland MW. Inhibition of pancreatic protein secretion by ghrelin in the rat. (2001) *J Physiol (Lond)* 537: 231–236.
79. Reimer MK, Pacini G and Ahren B. Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. (2003) *Endocrinology* 144: 916–921.
80. Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, Weintraub NL, and Tang C. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. (2004) *J Cardiovasc Pharmacol* 43: 165–170.
81. Chang L, Zhao J, Li GZ, Geng B, Pan CS, Qi YF, and Tang CS. Ghrelin protects myocardium from isoproterenol-induced injury in rats. (2004) *Acta Pharmacol Sin* 25: 1131–1137.
82. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, Hosoda H, Hirota Y, Ishida H, Mori H, Kangawa K. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. (2001) *Circulation* 104: 1430–5.
83. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, Hayashi Y, Kangawa K. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. (2001) *Am J Physiol: Regul Integr Comp Physiol* 280: R1483–R1487.
84. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, Hosoda H, Shimizu W, Yamagishi M, Oya H, Koh H, Yutani C, Kangawa K. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. (2001) *Circulation* 104: 2034–8.

85. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, Ueno K, Kitakaze M, Miyatake K, Kangawa K. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. (2004) *Circulation* 110: 3674-9.
86. Filigheddu N, Fubini A, Baldanzi G, Cutrupi S, Ghè C, Catapano F, Broglio F, Bosia A, Papotti M, Muccioli G, Ghigo E, Deghenghi R, Graziani A. Hexarelin protects H9C2 cardiomyocytes from doxorubicin-induced cell death. (2001) *Endocrine* 14: 113-119.
87. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonisconi S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. (2002) *J Cell Biol.* 159: 1029-37.
88. Bednarek MA, Feighner SD, Pong SS, McKee KK, Hreniuk DL, Silva MV, Warren VA, Howard AD, Van Der Ploeg LH, Heck JV. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. (2000) *J Med Chem* 43: 4370-4376.
89. Fukushima N, Hanada R, Teranishi H, Fukue Y, Tachibana T, Ishikawa H, Takeda S, Takeuchi Y, Fukumoto S, Kangawa K, Nagata K, Kojima M. Ghrelin directly regulates bone formation. (2005) *J Bone Miner Res* 20: 790-8.
90. Maccarinelli G, Sibilia V, Torsello A, Raimondo F, Pitto M, Giustina A, Netti C, Cocchi D. Ghrelin regulates proliferation and differentiation of osteoblastic cells. (2005) *J Endocrinol* 184: 249-56.
91. Groschl M, Topf HG, Bohlender J, Zenk J, Klusmann S, Dotsch J, Rascher W, Rauh M. Identification of Ghrelin in Human Saliva: Production by the Salivary Glands and Potential Role in Proliferation of Oral Keratinocytes. (2005) *Clin Chem* 51: 1-10.
92. De Vriese C, Gregoire F, De Neef P, Robberecht P, Delporte C. Ghrelin is produced by the human erythroleukemic HEL cell line and involved in an autocrine pathway leading to cell proliferation. (2005) *Endocrinology* 146: 1514-22.
93. Mazzocchi G, Neri G, Rucinski M, Rebuffat P, Spinazzi R, Malendowicz LK, Nussdorfer GG. Ghrelin enhances the growth of cultured human adrenal zona glomerulosa cells by exerting MAPK-mediated proliferogenic and antiapoptotic effects. (2004) *Peptides* 25: 1269-77.
94. Andreis PG, Malendowicz LK, Trejter M, Neri G, Spinazzi R, Rossi GP, Nussdorfer GG. Ghrelin and growth hormone secretagogue receptor are expressed in the rat adrenal cortex: Evidence that ghrelin stimulates the growth, but not the secretory activity of adrenal cells. (2003) *FEBS Lett* 536: 173-9.
95. Nanzer AM, Khalaf S, Mozid AM, Fowkes RC, Patel MV, Burrin JM, Grossman AB, Korbonits M. Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. (2004) *Eur J Endocrinol* 151: 233-40.
96. Kim MS, Yoon CY, Jang PG, Park YJ, Shin CS, Park HS, Ryu JW, Pak YK, Park JY, Lee KU, Kim SY, Lee HK, Kim YB, Park KS. The mitogenic and antiapoptotic actions of ghrelin in 3T3-L1 adipocytes. (2004) *Mol Endocrinol* 18: 2291-301.
97. Zhang W, Zhao L, Lin TR, Chai B, Fan Y, Gantz I, and Mulholland MW. Inhibition of adipogenesis by ghrelin. (2004) *Mol Biol Cell* 15: 2484-2491.
98. Duxbury MS, Waseem T, Ito H, Robinson MK, Zinner MJ, Ashley SW, Whang EE. Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. (2003) *Biochem Biophys Res Commun* 309: 464-8.
99. Pettersson I, Muccioli G, Granata R, Deghenghi R, Ghigo E, Ohlsson C, Isgaard J. Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. (2002) *J Endocrinol* 175: 201-9.
100. Jeffery PL, Herington AC, Chopin LK. Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. (2002) *J Endocrinol* 172: R7-11.
101. Cassoni P, Ghè C, Marrocco T, Tarabra E, Allia E, Catapano F, Deghenghi R, Ghigo E, Papotti M, and Muccioli G. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. (2004) *Eur J Endocrinol* 150: 173-184.
102. Volante M, Allia E, Fulcheri E, Cassoni P, Ghigo E, Muccioli G, Papotti M. Ghrelin in fetal thyroid and follicular tumors and cell lines: expression and effects on tumor growth. (2003) *Am J Pathol* 162: 645-54.
103. Ghè C, Cassoni P, Catapano F, Marrocco T, Deghenghi R, Ghigo E, Muccioli G, Papotti M. The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. (2002) *Endocrinology* 143: 484-91.
104. Cassoni P, Papotti M, Ghe C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, Muccioli G. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. (2001) *J Clin Endocrinol Metab* 86: 1738-45.

105. Barreiro ML, Gaytan F, Castellano JM, Suominen JS, Roa J, Gaytan M, Aguilar E, Dieguez C, Toppari J, Tena-Sempere M. Ghrelin inhibits the proliferative activity of immature Leydig cells in vivo and regulates stem cell factor messenger ribonucleic acid expression in rat testis. (2004) *Endocrinology* 145: 4825-34.
106. Xia Q, Pang W, Pan H, Zheng Y, Kang JS, Zhu SG. Effects of ghrelin on the proliferation and secretion of splenic T lymphocytes in mice. (2004) *Regul Pept* 122: 173-8.
107. Lluís F, Perdiguero E, Nebreda AR, and Muñoz-Canoves. Regulation of skeletal muscle gene expression by p38 MAP kinases. (2006) *TRENDS in Cell Biology* 16:36-43.
108. Pietrangelo A. Hereditary Hemochromatosis – A New Look at an Old Disease. (2004) *The New England Journal of Medicine* 350:2383-2397.
109. Franchini M. Hereditary Iron Overload: Update on Pathophysiology, Diagnosis, and Treatment. (2006) *American Journal of Hematology* 81:202-209.
110. Celec P. Hemojuvelin: a supposed role in iron metabolism one year after its discovery. (2005) *J. Mol. Med.* 83:521-525.
111. Pietrangelo A. Juvenile hemochromatosis. (2006) *Journal of Hepatology* 45:892-894.